http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018508495-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 |
| filingDate | 2016-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018508495-A |
| titleOfInvention | Prodrug and pharmaceutical composition of sunitinib |
| abstract | Structural formula (I) below (wherein R 12 and R 13 are H, C 1 -C 6 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, C 3 -C 8 cycloalkyl) R 14 is selected from the group consisting of a group, a C 6 -C 10 aryl group, a 4-15 membered heterocyclic group, and a 5-15 membered heteroaryl group, R 14 is R ′, OR ′, SR ′, and N (R ′ ) Selected from the group consisting of 2 , R ′ is H, C 1 -C 6 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, C 3 -C 8 cycloalkyl group, C 6 -C 10 aryl group, 4-15-membered heterocyclic group, heteroaryl group 5-15 membered, hydroxyl C 1 -C 6 alkyl group, a carboxyl C 1 -C 6 alkyl group, C 1 -C 6 alkylamido groups, and phosphorus Selected from the group consisting of acid groups). Buprodrugs have better pharmacokinetic and pharmacodynamic properties, better safety, and lower toxicity. [Chemical 1] |
| priorityDate | 2015-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 182.